Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer

被引:19
|
作者
Scheel, Andreas H. [1 ]
Penault-Llorca, Frederique [2 ]
Hanna, Wedad [3 ]
Baretton, Gustavo [4 ]
Middel, Peter [5 ,6 ]
Burchhardt, Judith [5 ]
Hofmann, Manfred [5 ]
Jasani, Bharat [7 ]
Rueschoff, Josef [5 ,7 ]
机构
[1] Univ Hosp Cologne, Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany
[2] Ctr Jean Perrin, Dept Pathol, 58 Rue Montalembert,392, F-63011 Clermont Ferrand 1, France
[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[4] Univ Hosp Dresden, Inst Pathol, Fetscherstr 74, D-01307 Dresden, Germany
[5] Inst Pathol Nordhessen, Germaniastr 7, D-34119 Kassel, Germany
[6] Univ Hosp Gottingen, Inst Pathol, Robert Koch Str 40, D-37075 Gottingen, Germany
[7] Targos Mol Pathol GmbH, Germaniastr 7, D-34119 Kassel, Germany
来源
DIAGNOSTIC PATHOLOGY | 2018年 / 13卷
关键词
HER2/neu; Immunohistochemistry; Breast cancer; Gastric cancer; Magnification rule; Predictive biomarker; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; DIGITAL IMAGE-ANALYSIS; AMERICAN-PATHOLOGISTS; PROTEIN EXPRESSION; ADENOCARCINOMAS; REPRODUCIBILITY; RECOMMENDATIONS; PEMBROLIZUMAB; VALIDATION;
D O I
10.1186/s13000-018-0696-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for efficient anti-HER2 treatment of breast and gastric carcinomas. Immunohistochemistry (IHC) of the HER2 protein is the most common screening test, thus precise and reproducible IHC-scoring is of utmost importance. Interobserver variance still is a problem; in particular in gastric carcinomas the reliable differentiation of IHC scores 2+ and 1+ is challenging. Herein we describe the physical basis of what we called the 'magnification rule': Different microscope objectives are employed to reproducibly subdivide the continuous spectrum of IHC staining intensities into distinct categories (1+, 2+, 3+). Methods: HER2-IHC was performed on 120 breast cancer biopsy specimens (n = 40 per category). Width and color-intensity of membranous DAB chromogen precipitates were measured by whole-slide scanning and digital morphometry. Image-analysis data were related to semi-quantitative manual scoring according to the magnification rule and to the optical properties of the employed microscope objectives. Results: The semi-quantitative manual HER2-IHC scores are correlated to color-intensity measured by image-analysis and to the width of DAB-precipitates. The mean widths +/- standard deviations of precipitates were: IHC-score 1+, 0.64 +/- 0.1 mu m; score 2+, 1.0 +/- 0.23 mu m; score 3+, 2.14 +/- 0.4 mu m. The width of precipitates per category matched the optical resolution of the employed microscope objective lenses: Approximately 0.4 mu m (40x), 1.0 mu m (10x) and 2.0 mu m (5x). Conclusions: Perceived intensity, width of the DAB chromogen precipitate, and absolute color-intensity determined by image-analysis are linked. These interrelations form the physical basis of the 'magnification rule': 2+ precipitates are too narrow to be observed with 5x microscope objectives, 1+ precipitates are too narrow for 10x objectives. Thus, the rule uses the optical resolution windows of standard diagnostic microscope objectives to derive the width of the DAB-precipitates. The width is in turn correlated with color-intensity. Hereby, the more or less subjective estimation of IHC scores based only on the staining-intensity is replaced by a quasi-morphometric measurement. The principle seems universally applicable to immunohistochemical stainings of membrane-bound biomarkers that require an intensity-dependent scoring.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Improving HER2 testing reproducibility in HER2-low breast cancer
    Sajjadi, Elham
    Venetis, Konstantinos
    Ivanova, Mariia
    Fusco, Nicola
    CANCER DRUG RESISTANCE, 2022, 5 (04) : 882 - 888
  • [42] Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK)
    Saito, Mayuko
    Yamashita, Kentaro
    Arimura, Yoshiaki
    Kaneto, Hiroyuki
    Okuda, Hiroyuki
    Nojima, Masanori
    Hagiwara, Takeshi
    Suzuki, Kazuya
    Adachi, Takeya
    Goto, Akira
    Nakachi, Kohei
    Yawata, Atsushi
    Yoshimoto, Mitsuru
    Tanuma, Tokuma
    Adachi, Yasushi
    Yamaoka, Satoshi
    Mizukoshi, Tsunenori
    Kawayama, Mariko
    Hamamoto, Yasuo
    Shinomura, Yasuhisa
    ACTA ONCOLOGICA, 2016, 55 (03) : 309 - 317
  • [43] Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks
    Ge, Xiaowen
    Wang, Haixing
    Zeng, Haiying
    Jin, Xuejuan
    Sujie, Akesu
    Xu, Chen
    Liu, Yalan
    Huang, Jie
    Ji, Yuan
    Tan, Yunshan
    Liu, Tianshu
    Hou, Yingyong
    Qin, Jing
    Sun, Yihong
    Qin, Xinyu
    HUMAN PATHOLOGY, 2015, 46 (06) : 850 - 857
  • [44] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [45] Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer
    Stahl, Phillip
    Seeschaaf, Carsten
    Lebok, Patrick
    Kutup, Asad
    Bockhorn, Maximillian
    Izbicki, Jakob R.
    Bokemeyer, Carsten
    Simon, Ronald
    Sauter, Guido
    Marx, Andreas H.
    BMC GASTROENTEROLOGY, 2015, 15
  • [46] HER2 in Breast Cancer: A Review and Update
    Krishnamurti, Uma
    Silverman, Jan F.
    ADVANCES IN ANATOMIC PATHOLOGY, 2014, 21 (02) : 100 - 107
  • [47] Her2 positive breast cancer: practices
    Campone, Mario
    Berton-Rigaud, Dominique
    Bourbouloux, Emmanuelle
    Sophie, Sadot
    Zanetti, Alain
    Frenel, Jean-Sebastien
    BULLETIN DU CANCER, 2011, 98 (02) : 154 - 163
  • [48] HER2/neu vaccines in breast cancer
    Khoo, Steven
    Ponniah, Sathibalan
    Peoples, George E.
    WOMENS HEALTH, 2006, 2 (02) : 217 - 223
  • [49] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [50] Assessment of HER2 status in breast cancer
    Penault-Llorca, F
    Cayre, A
    BULLETIN DU CANCER, 2004, 91 : S211 - S215